采用MATILDE方案后进行放疗是一种针对原发性中枢神经系统淋巴瘤的积极治疗策略。
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
作者信息
Ferreri A J M, Dell'Oro S, Foppoli M, Bernardi M, Brandes A A, Tosoni A, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Ponzoni M, Picozzi P, Caligaris Cappio F, Reni M
机构信息
Medical Oncology Unit, San Raffaele H Scientific Institute, Università Vita-Salute San Raffaele, Milan, Italy.
出版信息
Neurology. 2006 May 9;66(9):1435-8. doi: 10.1212/01.wnl.0000210464.94122.e1.
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
作者在一项II期试验中评估了MATILDE化疗方案，随后对41名70岁及以下的原发性中枢神经系统淋巴瘤患者进行了根据反应调整的放射治疗。MATILDE化疗后的缓解率为76%，化疗联合或不联合放射治疗后的缓解率为83%，这是一种有效的策略，尤其是在低至中危患者（国际结外淋巴瘤研究组[IELSG]评分）中。骨髓抑制是剂量限制性毒性，致死性并发症发生率为9.5%。中位随访49个月后，生存曲线出现平台期（5年总生存率：41±7%）。
Zotero 插件